All In Biotech

Drug Trial Radar · NCT07418177

Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD

Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Advanced (Late-stage) Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Oct 14, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
HELP Therapeutics Co., Ltd.
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.

Conditions

  • AMD - Age-Related Macular Degeneration

Interventions

  • hiPSC-RPEsBiological

    hiPSC-RPEs transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-Related Adverse EventsTime frame: Within 2 years after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital with Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.